Bris­tol My­ers Squibb gets pri­or­i­ty re­view for AML drug as list of po­ten­tial Cel­gene hits length­ens

Po­ten­tial ap­provals keep emerg­ing out of Cel­gene’s old line­up.

To­day, the FDA ac­cept­ed and gave pri­or­i­ty re­view to CC-486, an acute myeloid leukemia drug that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER